Comparative Pharmacology
Head-to-head clinical analysis: MONISTAT 3 versus NILSTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MONISTAT 3 versus NILSTAT.
MONISTAT 3 vs NILSTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Miconazole nitrate, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity and cause leakage of intracellular contents, leading to fungal cell death.
One vaginal suppository (200 mg miconazole nitrate) intravaginally at bedtime for 3 consecutive days; or one applicatorful (5 g) of 4% vaginal cream intravaginally at bedtime for 7 days.
Topical: Apply 100,000 units/g cream or ointment to affected area twice daily. Oral suspension: 100,000 units/mL; 4-6 mL swish and swallow four times daily for 14 days. Oral tablets: 500,000 units; 1-2 tablets three times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 30 hours after topical vaginal application; prolonged in hepatic impairment.
Not well-defined due to minimal systemic absorption following oral or topical administration; estimated to be <1 hour in systemic circulation if absorbed.
Primarily fecal (97%) via biliary excretion; renal excretion of unchanged drug is negligible (<1%).
Primarily via feces as unchanged drug; negligible urinary excretion (<1%).
Category C
Category C
Antifungal
Antifungal